■评估肝细胞癌(HCC)患者与对照组以及慢性肝炎(CH)和肝硬化(LC)患者的血清白细胞介素8(IL-8)水平。
■三个数据库,即PubMed,WebofScience,还有Scopus,在2017年11月之前进行了搜索,没有语言限制。RevMan5.3版中的随机效应分析使用平均差(MD)和95%置信区间(CI),并进行敏感性分析作为次要分析。
■在239项研究中发现,10项研究招募659名HCC患者,237个控件,357例LC患者,纳入48例CH患者并进行荟萃分析。合并的MD为39.48(95CI:152.31,406.47,p<0.00001),21.32(95%CI:-6.04,48.68,p=0.13),和36.46(95%CI:21.77,51.15,p<0.00001)在肝癌患者与对照组相比,LC和CH患者,分别。
■与其他三组相比,HCC患者的血清IL-8水平升高显示HCC患者中这种细胞因子的风险增加。因此,这种白细胞介素可作为替代甲胎蛋白(AFP)的新生物标志物,或作为评估HCC发病机制和可能的进展或发展的临床检测方法.
UNASSIGNED: To estimate serum interleukin 8 (IL-8) level in patients with hepatocellular carcinoma (HCC) compared to controls and patients with chronic hepatitis (CH) and liver cirrhosis (LC).
UNASSIGNED: Three databases, i.e. PubMed, Web of Science, and Scopus, were searched up to November 2017 without language restriction. The mean difference (MD) and 95% confidence interval (CI) were used by a random-effects analysis in RevMan version 5.3, and sensitivity analysis was performed as the secondary analysis.
UNASSIGNED: Out of 239 studies found, 10 studies recruiting 659 HCC patients, 237 controls, 357 patients with LC, and 48 patients with CH were included and analyzed in the meta-analysis. The pooled MDs were 39.48 (95%CI: 152.31, 406.47, p < 0.00001), 21.32 (95% CI: -6.04, 48.68, p = 0.13), and 36.46 (95% CI: 21.77, 51.15, p < 0.00001) in the patients with HCC compared to the controls, the patients with LC and those with CH, respectively.
UNASSIGNED: An elevated serum IL-8 level in the HCC patients compared to the three other groups showed an increased risk for this cytokine in HCC patients. Therefore, this interleukin can be used as a new biomarker replacing alpha-fetoprotein (AFP) or as a clinical assay for evaluation of the pathogenesis and probably the progression or development of HCC.